

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited

中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2361)

POSITIVE PROFIT ALERT

This announcement is made by Sinohealth Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Company would like to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the “**First Half of 2023**”) and the information currently available to the Company, the Company’s profit ranged from approximately RMB40 million to RMB50 million during the First Half of 2023, which has increased significantly by approximately 700% to 900% as compared to approximately RMB5 million for the six months ended 30 June 2022.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is of the view that the increase in profit was mainly attributable to (i) the continued increase in revenue from main business as compared to the corresponding period of last year as a result of the increased demand for digitalisation of the healthcare industry during the First Half of 2023. In particular, the Smart Decision Cloud, a comprehensive solution that combines a variety of digital insight products and professional services, can effectively help customers improve decision-making efficiency and achieve business goals; (ii) the comprehensive enhancement of the Group’s efficiency in operational management and market expansion during the First Half of 2023; and (iii) in part, the increase in other incomes and gains such as foreign exchange gains and interest income.

The Board believes that the Group’s strategic positioning of a vertical cloud platform in the healthcare industry will better align with the industry’s development trend, particularly with the emergence of new markets created by the upgrading of patient needs and the opportunities brought by the digital economy. The Group will adhere to a patient-centered approach, focus on providing SaaS products and professional services to all stakeholders in the healthcare industry, and establish a healthcare industry ecological platform, thereby achieving a closed-loop life-cycle health management system that integrates the elements of “prevention, treatment, maintenance, body and mind”, and ultimately becoming a world-leading digital technology company in the field of life science.

As at the date of this announcement, the Company is currently in the process of finalizing the interim results of the Group for the First Half of 2023. The information as set out in this announcement is the Board's preliminary assessment with reference to the Group's unaudited consolidated management accounts for the First Half of 2023 and the information currently available to the Board which has not been reviewed and confirmed by the Company's independent auditors or reviewed by the audit committee of the Company and is subject to adjustments. The Company's interim results for the First Half of 2023 are expected to be published by the end of August, in compliance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 4 August 2023

As at the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Du Yilin and Mr. Wei Bin.